The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Molecular Medicine
PreviousPrevious
Volume 333:1554-1556 December 7, 1995 Number 23
NextNext

Muscle-Mediated Gene Therapy

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Many of the problems and hopes associated with gene therapy are exemplified in preclinical studies of genetically altered muscle cells (skeletal, cardiac, and smooth). Smooth-muscle cells of the arterial wall are being genetically engineered to synthesize growth inhibitors that might prevent restenosis after balloon angioplasty. In animal models, the injection into cardiac muscle of genes that induce new vessel formation may lead to increased blood flow. Perhaps most surprising is the finding that skeletal-muscle cells can be used as recombinant-protein factories that produce and secrete proteins that can act either locally in muscle or distally.

A number of approaches involving . . . [Full Text of this Article]


Source Information

From the Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, CA 94305-5332, where reprint requests should be addressed to Dr. Blau.

Recommended Reading


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.